SPONSORED BY SICA MEDIA AND DISSEMINATED ON BEHALF OF ORAGENICS, INC.*

Hey again Market Enthusiast!

🚨 BREAKING UPDATE: CLINICAL OPERATIONS COMMENCED The wait is over. As of this morning, March 12, 2026, the strategy has shifted from preparation to active execution. The first Phase IIa clinical trial site initiation visit (SIV) in Australia is now officially complete. This marks the formal launch of clinical operations, with staff training and protocol orientation finalized at the lead site. (9)

A FAST-MOVING CATALYST With the first site now operational and the remaining two in the final stages of administrative review, the timeline for patient dosing has moved to "imminent." This is the disciplined, rapid-fire execution that defines a category leader. When you pair this clinical milestone with yesterday's "bombshell" announcement regarding an aggressive acquisition strategy, you are looking at a CNS powerhouse being built in real-time. The window to watch this setup before the next major headline is shrinking fast. (9)

THE BIOTECH SHIFT NO ONE SAW COMING (1)(8)

Listen up. While most people are staring at the same tired screens, a massive revolution is quietly detonating in the world of brain health.

Right now, there is a total void in how the world addresses head-impact recovery. Zero. Zilch. Nada. For decades, the "standard" has been "sit in a dark room and wait." It’s an antiquated approach that leaves millions of people—from professional athletes to weekend warriors—simply hoping for the best. But that era of doing nothing is officially ending.

Oragenics, Inc. (NYSE American: OGEN) isn't just participating in this change—they are defining the category. We’re talking about a high-velocity team tackling a $9 Billion problem with a solution that actually targets the biology of the injury. If you aren’t watching Oragenics, Inc. (NYSE American: OGEN) today, you’re missing what could be the most significant setup of 2026.

(6)

WHY THE BUZZ IS GLOWING RED HOT (1)(3)(4)(5)(6)

The chatter surrounding Oragenics, Inc. (NYSE American: OGEN) has reached a fever pitch, and for good reason. The movement we’ve seen recently is exactly the kind of action that keeps enthusiasts awake at night.
 

• PREVIOUS FIREWORKS: When the spotlight first hit last month, Oragenics, Inc. (NYSE American: OGEN) saw a surge as high as +42% intraday. That wasn’t just a fluke; it was a loud-and-clear signal of what this profile is capable of when the news hits the wire.
   
• THE MOMENTUM IS REAL: This name is up +36% over the last month and +18% in just the last 5 trading days. The movement is steady, intentional, and picking up steam.
   
• LOW FLOAT PROFILE: Because Oragenics, Inc. (NYSE American: OGEN) has a relatively small float and a sub-$1 price point, it acts like a coiled spring. In this world, news travels fast, and the energy can become vertical in a heartbeat. You do not want to be the person checking the company after the "big move" has already happened.
   

THE "MIND-BLOWING" TECH: DIRECT-TO-BRAIN DELIVERY (1)(2)(5)(7)

Why is this different? Because Oragenics, Inc. (NYSE American: OGEN) has a proprietary, "blow-activated" device that sends the solution directly to the brain through the olfactory and trigeminal nerve pathways.

Think about that for a second. No injections. No waiting for a pill to digest. Oragenics, Inc. (NYSE American: OGEN) is using a non-invasive, "Brain-First Recovery" system that bypasses the blood-brain barrier—the biggest hurdle in neuroscience. It’s fast, it’s portable, and it’s field-ready.

The Reality Check:
 

• 69 Million annual occurrences worldwide.
• 30-80% of those people develop long-term symptoms.
• $9 Billion projected sector.
• 2040+ IP protection keeps the competition at bay for decades.
   

🚨 JUST RELEASED: THE GAME-CHANGER NEWS 🚨  (1)(2)(5)(8)

DATE: March 11, 2026

As if the breakthrough with their lead candidate wasn't enough, Oragenics, Inc. (NYSE American: OGEN) just recently dropped a bombshell. They aren't just a "one-asset" story anymore.

Oragenics, Inc. (NYSE American: OGEN) just announced they are officially exploring acquisitions. They are actively looking to acquire assets in brain health, recovery, and neuroprotection to build a massive Central Nervous System (CNS) powerhouse. They are combining AI-driven discovery with aggressive acquisition strategies. This is how giants are built.

"We believe our intranasal delivery platform is not a single-drug asset... our goal is to build a CNS company that makes a meaningful impact on how the world treats diseases of the brain." — Janet Huffman, CEO of Oragenics, Inc. (NYSE American: OGEN)

By expanding their portfolio, Oragenics, Inc. (NYSE American: OGEN) is positioning themselves to dominate the entire landscape of brain recovery, not just one specific injury type.

THE CLOCK IS TICKING: MARCH IS THE MONTH

If you’ve been waiting for a "sign," this is it. The catalysts for Oragenics, Inc. (NYSE American: OGEN) are lined up like a row of dominos ready to fall.
 

1. HREC Approval? DONE (As of March 10!). ✅ 
   This means the clinical trial sites in Australia are officially greenlit.
    
2. First Patient Dosing? Expected BEFORE THE END OF MARCH. ⏳ We are talking days, not months.
    
3. Phase 2a Data Readout? Targeted for Q4 2026. 📊
    

The window to get ahead of the crowd is closing. By the time the Phase 2 data is on the evening news, the "early" potential will be long gone. The clinical sites are being initiated by Oragenics, Inc. (NYSE American: OGEN) right now. The patients are being lined up. This is happening in real-time.

THE "DREAM TEAM" BEHIND THE CURTAIN (1)(2)(5)(6)(7)(8)

You don't tackle the most prominent neurological condition in the world with a "B" team. Oragenics, Inc. (NYSE American: OGEN) is led by the heavy hitters who have spent their lives in the trenches of brain science:
 

• Dr. James Kelly: Former Director of the National Intrepid Center of Excellence at Walter Reed. He is the man who treats our nation’s heroes. He literally wrote the book on brain injury.
   
• Dr. Frank Peacock: A world-renowned expert from Baylor College of Medicine and a giant in the world of emergency medicine research.
   
• Janet Huffman: A veteran leader with a track record of scaling high-growth ventures and leading successful mergers.
   

When people like this attach their names to Oragenics, Inc. (NYSE American: OGEN), you pay attention.

WHY THIS IS ON THE RADAR RIGHT NOW

We look for three things: Massive Unmet Need, Proprietary Tech, and Imminent Catalysts. Oragenics, Inc. (NYSE American: OGEN) just checked all three boxes, then added a "Bonus Round" with today's acquisition news.

The market for brain health is projected to hit $100 Billion+ by 2030. There are no leaders. There are no approved pharmacological fixes. Oragenics, Inc. (NYSE American: OGEN) is standing alone at the starting line, holding the keys to the only clinical-stage solution with an FDA pathway.

This is about more than just numbers—it’s about a fundamental shift in how we protect the human brain. Oragenics, Inc. (NYSE American: OGEN) is at the heart of that shift.

Don't be the one reading the "I told you so" report in April. Get Oragenics, Inc. (NYSE American: OGEN) on your screen, set your alerts, and watch this space closely. 

The momentum is building, the news is breaking, and the first patient is about to change history.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:

1. https://finance.yahoo.com/quote/OGEN/
2. https://finance.yahoo.com/quote/OGEN/key-statistics/
3. https://www.oragenics.com/
4. https://ir.oragenics.com/
5. https://finance.yahoo.com/news/oragenics-partners-duck-flats-pharma-133000379.html
6. https://finance.yahoo.com/news/oragenics-targets-projected-9-billion-133000010.html
7. https://finance.yahoo.com/news/oragenics-receives-hrec-approval-phase-123000205.html
8. https://finance.yahoo.com/news/oragenics-explores-expansion-cns-platform-123000208.html
9. https://finance.yahoo.com/news/oragenics-initiates-phase-iia-clinical-123000782.html

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 03/11/2026 and ending on 03/12/2026 (the “Campaign”) to publicly disseminate information about Oragenics, Inc. (OGEN:US). Momentum Media LLC has been compensated $5,000 and are owed an additional $0 for the Campaign. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.